Navigation Links
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
Date:10/17/2007

.pharmion.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements relating to the planned development program for amrubicin, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Pharmion's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include, but are not limited to, the potential failure of amrubicin, to demonstrate safety and efficacy in the Phase 3 study discussed in this release or in other clinical and non-clinical testing; the ability to complete regulatory submissions and gain regulatory approvals in a timely manner; the ability to initiate and complete trials at the referenced times; the impact of competition from other products under development by Pharmion's competitors; the uncertainty of the regulatory environment and changes in the health policies of various countries; acceptance and demand for new pharmaceutical products and new therapies; uncertainties regarding market acceptance of products newly launched, currently being sold or in development; failure of third-party manufacturers to produce the product volumes required on a timely basis and fluctuations in currency exchange rates. Additional risks and uncertainties relating to Pharmion and its business can be found in the "Risk Factors" section of Pharmion's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2007, its Annual Report on Form 10-K for the year ended December 31, 2006 and in our other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and Pharmion undertakes no o
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Malvern initiates European user group meetings for chemical imaging
4. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
7. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
10. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
11. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... and PARIS , July ... REGN ) and Sanofi (EURONEXT: SAN and NYSE: ... 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia ... reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at ... is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase ...
(Date:7/30/2014)...  Packaging Coordinators, Inc. (PCI) is pleased to announce ... Pharmaceutical Services Limited (Penn Pharma). Penn Pharma is headquartered in ... United Kingdom and operates regional offices ... Tokyo , Japan. Penn Pharma offers both ... dosage form manufacturing, as well as Clinical Packaging, Labeling, ...
(Date:7/30/2014)... FOREST, Ill., July 30, 2014  Hospira, Inc. ... provider of injectable drugs and infusion technologies, today ... 30, 2014. Net sales for the quarter were ... were $0.72. (Adjusted* measures exclude specified items as ... attached schedules.) On a U.S. Generally Accepted Accounting ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25
(Date:7/30/2014)... July 30, 2014 Everyone knows that the ... basically everyone. Whether people are looking for something to buy, ... a dentist, the internet is pretty much always going to ... Dental in Lauderdale Florida is so happy to announce the ... web presence into the modern age. Whether a person wants ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 With the recent ... Ground Zero, the Ground Zero Museum Workshop in the Meatpacking ... bookings. Says the Museum Workshop's Carole Barnes, "We have had ... all the major travel sites who sell us so tourists ... crystal clear as to what we do and what the ...
(Date:7/30/2014)... Decene is an alkene with the formula C10H20. ... with one double bond. 1-Decene enters all reactions ... used as a co-monomer in certain copolymers and ... alcohols, synthetic lubricants, synthetic fatty acids, and alkylated ... customization on this report. , http://www.micromarketmonitor.com/contact/2523613387-request_for_customization.html ...
(Date:7/30/2014)... July 30, 2014 The Europe Phytochemicals ... Phytochemicals & plant extracts market in Europe with analysis ... market in Europe is estimated to grow from around ... at a CAGR of 8.4%, for the given period. ... & plant extracts market report, to get an idea ...
(Date:7/30/2014)... diagnosed with depression as preschoolers are likely to suffer ... research shows. , Depressed preschoolers were 2.5 times more ... middle school than kids who were not depressed at ... School of Medicine in St. Louis. , Their study ... American Journal of Psychiatry . , "It,s the same ...
Breaking Medicine News(10 mins):Health News:Sierra Dental Releases New Website For Fort Lauderdale Residents 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 3Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 4Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 5Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 2Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 3Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Many depressed preschoolers still suffer in later school years 2Health News:Many depressed preschoolers still suffer in later school years 3
... Some complications may occur in children receiving cochlear implants, ... area and inner ear malformation, according to a report ... & Neck Surgery , one of the JAMA/Archives journals. ... provide a sense of sound to individuals who are ...
... cartilage to plates made of the resorbable material polydioxanone ... the thin cartilage separating the two airways, according to ... of Facial Plastic Surgery , one of the JAMA/Archives ... deviated septum, is not always possible because the surgical ...
... simple question of male patients , MONDAY, Jan. 18 ... sign that a man might be at increased risk ... long-running study indicates. , "We saw that adjusting for ... erectile function still had a 40 percent increased risk," ...
... as well as other meds, study finds, , MONDAY, ... psoriasis is rising faster than inflation, says a U.S. ... more than traditional systemic therapies. , The researchers created ... systemic therapy for psoriasis, a chronic autoimmune skin disease ...
... benefits vs. risks, researchers say , MONDAY, Jan. 18 (HealthDay ... most of the five percent of Americans who are very ... researchers at the University of Cincinnati, concluded that the benefits ... for most people who are morbidly obese, which is defined ...
... to contribute to heart disease, researchers say , MONDAY, Jan. ... restaurants are immersed in corn-based oil -- usually considered the ... to the authors of a new study. , Corn oil ... heart disease. , This type of oil is also ...
Cached Medicine News:Health News:Complications common, often linked to trauma in children receiving cochlear implants 2Health News:Synthetic, dissolving plates ease repairs of nasal septum defects 2Health News:Erectile Dysfunction Predicts Heart Disease 2Health News:Cost of Psoriasis Drugs Rising Faster Than Others 2Health News:For Very Obese, Gastric Bypass May Extend Life 2Health News:For Very Obese, Gastric Bypass May Extend Life 3Health News:Most Fast-Food French Fries Cooked in Unhealthiest Oil 2Health News:Most Fast-Food French Fries Cooked in Unhealthiest Oil 3
8 mm diameter curved probes with suture eyes just back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.6 inches....
The Novus 2000 argon laser combines power, size, and versatility. Ideal for the office, clinic and operating room environments, Novus 2000 is the world's most widely accepted ophthalmic laser....
The Meridian Microruptor V Nd: YAG laser system is indicated for posterior capsulotomy, peripheral iridotomy, and pupillary membranectomy procedures....
Two point fixation, tips separated by 13 mm. Each tip has 0.12 mm, 1 x 2 teeth. Wide serrated handle with thumb catch lock and dull finish....
Medicine Products: